Prescribing Information
... administration of apraclonidine HCl to rats and mice at dosages of 1 and 0.6 mg/kg/day, up to 50 and 30 times, respectively, the maximum dose recommended for human topical ocular use. Apraclonidine HCl was not mutagenic in a series of in vitro mutagenicity tests, including the Ames test, a mouse lym ...
... administration of apraclonidine HCl to rats and mice at dosages of 1 and 0.6 mg/kg/day, up to 50 and 30 times, respectively, the maximum dose recommended for human topical ocular use. Apraclonidine HCl was not mutagenic in a series of in vitro mutagenicity tests, including the Ames test, a mouse lym ...
PDF, 623 KB - Center for the Study of Democracy
... use predetermine different consequences for differenet groups as related to the ban of the personal use dose. As has been mentioned previously, the analysis in this text will be limited to the heroin injection drug users (IDU). However, national studies have established that heroin drug users are us ...
... use predetermine different consequences for differenet groups as related to the ban of the personal use dose. As has been mentioned previously, the analysis in this text will be limited to the heroin injection drug users (IDU). However, national studies have established that heroin drug users are us ...
Tonix Pharmaceuticals - Edison Investment Research
... pharmacological therapies, some of which are used off label after SSRI failure, meaningful effect sizes were generally seen only in small trials (the effect size for topiramate is heavily skewed by a 67-patient trial in Iran where the drug was tested as adjunct therapy rather than monotherapy for PT ...
... pharmacological therapies, some of which are used off label after SSRI failure, meaningful effect sizes were generally seen only in small trials (the effect size for topiramate is heavily skewed by a 67-patient trial in Iran where the drug was tested as adjunct therapy rather than monotherapy for PT ...
Data Sheet
... Prinzmetal's angina (variant angina pectoris). Relatively selective beta1-receptor blockers, such as Lopresor, can be used in such patients, but only with the utmost care. ...
... Prinzmetal's angina (variant angina pectoris). Relatively selective beta1-receptor blockers, such as Lopresor, can be used in such patients, but only with the utmost care. ...
Drug-Drug Interactions Discovery Based on CRFs SVMs and Rule-Based Methods
... The use of medications has a central role in health care provision, yet on occasion it may endanger patients’ safety and account for increased health care costs, as result of adverse drug events (ADEs). Many of these injuries are inevitable, but at least a quarter may be secondary to medication erro ...
... The use of medications has a central role in health care provision, yet on occasion it may endanger patients’ safety and account for increased health care costs, as result of adverse drug events (ADEs). Many of these injuries are inevitable, but at least a quarter may be secondary to medication erro ...
Oxcarbazepine (TrileptalTM)
... The FDA, however, does not indicate that a generic drug can be substituted by another generic drug for a brand name drug product even though both of the generic drugs have been shown to be bioequivalent to the same brand name drug. Bioequivalence studies are generally performed on a limited number o ...
... The FDA, however, does not indicate that a generic drug can be substituted by another generic drug for a brand name drug product even though both of the generic drugs have been shown to be bioequivalent to the same brand name drug. Bioequivalence studies are generally performed on a limited number o ...
NOVEL DRUG DELIVERY SYSTEMS FOR ANTIFUNGAL THERAPY Review Article SADHNA KHATRY *, SIRISH
... which are molecules that have a head group and a tail group. The head is attracted towards water, and the tail, which is made of a long hydrocarbon chain, is repelled by water. Liposomes can be filled with drugs, and used for delivering drugs for cancer and other diseases. The major ...
... which are molecules that have a head group and a tail group. The head is attracted towards water, and the tail, which is made of a long hydrocarbon chain, is repelled by water. Liposomes can be filled with drugs, and used for delivering drugs for cancer and other diseases. The major ...
highlights of prescribing information
... positive for binding antibodies, one patient developed neutralizing antibodies. The impact of antibody formation on pharmacokinetics, safety and efficacy of peg-interferon alfa-2b could not be assessed based on limited available data. The incidence of antibody formation is highly dependent on the se ...
... positive for binding antibodies, one patient developed neutralizing antibodies. The impact of antibody formation on pharmacokinetics, safety and efficacy of peg-interferon alfa-2b could not be assessed based on limited available data. The incidence of antibody formation is highly dependent on the se ...
Core Aspects of Clinical Development and Trials in Chronic
... normal bowel function. The benefit of this approach is the ability to establish preliminary pharmacokinetics and safety profiles in subjects without significant pre-existing conditions. These compounds induce defecatory changes in healthy volunteers, such as increasing bowel movement frequency. Howe ...
... normal bowel function. The benefit of this approach is the ability to establish preliminary pharmacokinetics and safety profiles in subjects without significant pre-existing conditions. These compounds induce defecatory changes in healthy volunteers, such as increasing bowel movement frequency. Howe ...
ADENOSINE (Adenocard) - Department of Emergency Management
... VF or pulseless VT only: 5 mg/kg IV or IO bolus; maximum dose 300 mg. NOTES: Do not administer if patient is hypotensive. Stop administration if patient becomes hypotensive during treatment. Do not administer with bicarbonate in the same IV line (will precipitate). When creating infusion, ...
... VF or pulseless VT only: 5 mg/kg IV or IO bolus; maximum dose 300 mg. NOTES: Do not administer if patient is hypotensive. Stop administration if patient becomes hypotensive during treatment. Do not administer with bicarbonate in the same IV line (will precipitate). When creating infusion, ...
Aubagio Prescribing Information
... clinical trials of AUBAGIO but rare cases of pancytopenia and agranulocytosis have been reported in the postmarketing setting with leflunomide. A similar risk would be expected for AUBAGIO [see Clinical Pharmacology (12.3)]. Cases of thrombocytopenia with AUBAGIO, including rare cases with platelet ...
... clinical trials of AUBAGIO but rare cases of pancytopenia and agranulocytosis have been reported in the postmarketing setting with leflunomide. A similar risk would be expected for AUBAGIO [see Clinical Pharmacology (12.3)]. Cases of thrombocytopenia with AUBAGIO, including rare cases with platelet ...
DSQ Fall 2013 - American College of Rheumatology
... hampers the interpretation of these studies. Taken together, current data suggests that methotrexate can be continued in the perioperative period to avoid flare, without impairing wound healing or increasing the infection risk. ...
... hampers the interpretation of these studies. Taken together, current data suggests that methotrexate can be continued in the perioperative period to avoid flare, without impairing wound healing or increasing the infection risk. ...
Adverse reaction to Amoxicillin: a case report
... Type II (cytotoxic antibodies, often involving complement), Type III (antigen-antibody immune complex and complementamplified reaction) and Type IV (cell-mediated hypersensitivity).7,8,13 However, certain immunopathological reactions do not fit into this classification, such as the maculopapular ras ...
... Type II (cytotoxic antibodies, often involving complement), Type III (antigen-antibody immune complex and complementamplified reaction) and Type IV (cell-mediated hypersensitivity).7,8,13 However, certain immunopathological reactions do not fit into this classification, such as the maculopapular ras ...
PROTOCOL NUMBER: 120-SCD1
... after dosing with NKTT120 and to correlate the PK and PD profiles. It is anticipated that iNKT cells will recover after NKTT120 is eliminated from or is present at very low concentrations in the serum. Safety: Only one subject will be dosed on any day. Subjects will be monitored in the clinical tria ...
... after dosing with NKTT120 and to correlate the PK and PD profiles. It is anticipated that iNKT cells will recover after NKTT120 is eliminated from or is present at very low concentrations in the serum. Safety: Only one subject will be dosed on any day. Subjects will be monitored in the clinical tria ...
Evaluation By Membrane Diffusion And Confocal Microscopy
... nuclei (dark spaces) did not take up Nile red at all. Larger emzaloids (> 1 µm) were not present in this optical plane. ...
... nuclei (dark spaces) did not take up Nile red at all. Larger emzaloids (> 1 µm) were not present in this optical plane. ...
12th Lecture 1435
... Because trimethoprim is more lipid-soluble than sulfamethoxazole, it has a larger volume of distribution than the latter drug Therefore, when 1 part of trimethoprim is given with 5 parts of sulfamethoxazole (the ratio in the formulation), the peak plasma concentrations are in the ratio of 1:20, ...
... Because trimethoprim is more lipid-soluble than sulfamethoxazole, it has a larger volume of distribution than the latter drug Therefore, when 1 part of trimethoprim is given with 5 parts of sulfamethoxazole (the ratio in the formulation), the peak plasma concentrations are in the ratio of 1:20, ...
Reinforcing Effects of Psychostimulants in Humans Are Associated
... the Diagnostic and Statistics Manual IV (DSM IV; American Psychiatric Association) (excluding nicotine/caffeine). Subjects were excluded if they had a current or past psychiatric, neurological, cardiovascular, or endocrinological disease. None of the subjects was taking medications at the time of th ...
... the Diagnostic and Statistics Manual IV (DSM IV; American Psychiatric Association) (excluding nicotine/caffeine). Subjects were excluded if they had a current or past psychiatric, neurological, cardiovascular, or endocrinological disease. None of the subjects was taking medications at the time of th ...
Statistical Challenges in the Validation of Surrogate Endpoints
... arm compared to 26 in the placebo arm (p=0.0001). After continuing the trial with moricizine as the only active arm (CASTII), there was excess mortality in moricizine arm alone (17 deaths in 665 patients) as compared to no therapy or placebo group (3 deaths in 660 patients). This study had to be t ...
... arm compared to 26 in the placebo arm (p=0.0001). After continuing the trial with moricizine as the only active arm (CASTII), there was excess mortality in moricizine arm alone (17 deaths in 665 patients) as compared to no therapy or placebo group (3 deaths in 660 patients). This study had to be t ...
Suggestion from clinicians
... chronic heart failure has not been investigated, except in isolated trials,so we decided to pool the data from different trials to assess the important question of tolerability and the discontinuation rates of different β blockers in heart failure with reduced ejection fraction.43 Our analysis reass ...
... chronic heart failure has not been investigated, except in isolated trials,so we decided to pool the data from different trials to assess the important question of tolerability and the discontinuation rates of different β blockers in heart failure with reduced ejection fraction.43 Our analysis reass ...
Single-Dose Oritavancin Versus 7–10 Days of
... SOLO II was a phase 3, global, multicenter, randomized, double-blind, comparative efficacy and safety study evaluating single-dose intravenous oritavancin vs intravenous vancomycin for 7–10 days in adults with ABSSSIs comprising wound infection, cellulitis, and major cutaneous abscess. The study desi ...
... SOLO II was a phase 3, global, multicenter, randomized, double-blind, comparative efficacy and safety study evaluating single-dose intravenous oritavancin vs intravenous vancomycin for 7–10 days in adults with ABSSSIs comprising wound infection, cellulitis, and major cutaneous abscess. The study desi ...
ROLE OF MULTIPLE ION CHANNEL BLOCKER –AMIODARONE IN MODEL OF... LOCOMOTOR ACTIVITY AND COGNITION IN ALBINO RATS
... PTZ-induced model, the most popular and widely used animal seizure model, represents a valid model for human generalized myoclonic and also absence seizures, and this test has been used primarily to evaluate anticonvulsant drugs [7].Although convulsive activity of PTZ is not fully understood, it has ...
... PTZ-induced model, the most popular and widely used animal seizure model, represents a valid model for human generalized myoclonic and also absence seizures, and this test has been used primarily to evaluate anticonvulsant drugs [7].Although convulsive activity of PTZ is not fully understood, it has ...
Targeting mononuclear phagocytes for eradicating
... flow cytometry and observed a remarkable selectivity of PMPC-PDPA polymersomes for monocytes (Ly6C+ cells) with over 98% of these positive only 5min after i.v. injection (Figure 3b). This is in contrast to about 12% of B cells, 7% of T cells and 6% of neutrophils while red blood cells did not show an ...
... flow cytometry and observed a remarkable selectivity of PMPC-PDPA polymersomes for monocytes (Ly6C+ cells) with over 98% of these positive only 5min after i.v. injection (Figure 3b). This is in contrast to about 12% of B cells, 7% of T cells and 6% of neutrophils while red blood cells did not show an ...
BENICAR® Fact Sheet
... Morbidity in Infants: Children <1 year of age must not receive BENICAR for hypertension. Fetal Toxicity: BENICAR and BENICAR HCT are Pregnancy Category D. Hypotension in Volume- or Salt-Depleted Patients: In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted pa ...
... Morbidity in Infants: Children <1 year of age must not receive BENICAR for hypertension. Fetal Toxicity: BENICAR and BENICAR HCT are Pregnancy Category D. Hypotension in Volume- or Salt-Depleted Patients: In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted pa ...